MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijantimicag.2026.107787

Медицинская библиотека · International journal of antimicrobial agents · 2026

ESBL-producing Escherichia coli bacteraemic urinary tract infections: Clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study.

Gómez-Zorrilla Silvia, Rodríguez-Cabalé Grethel, López Montesinos Inmaculada, Alanti Soukaina Sara, Franquet Alejandra, Pascual-Aranda Mariano, Alonso-Carrillo Jesús, Rodríguez-Alarcón Alicia, Sendra Elena, Siverio Ana, Esteban-Cucó Sandra, Sabaté Rosa Ana, Duran-Jordà Xavier, Grau Santiago, Rodríguez-Baño Jesús, Horcajada Juan P, PROA-HMAR

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The study aimed to assess the clinical and economic impact of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli bacteraemic UTIs (Ec-BUTI) and to evaluate the possibility of developing antimicrobial stewardship interventions.

METHODS

Retrospective single-centre cohort study included all consecutive episodes of Ec-BUTI requiring hospitalisation from September 2020 to February 2023.

PRIMARY OUTCOME: clinical failure.

SECONDARY OUTCOME: hospital resource consumption, length of stay, 30-d recurrence and mortality and 90-d readmissions. Antimicrobial stewardship interventions were evaluated. A propensity score matching analysis was performed.

RESULTS

Three hundred ten E. coli-BUTI episodes were included; 86 caused by ESBL-producing strains. The ESBL group had greater comorbidity burden than the non-ESBL group (median Charlson index 4 [IQR 2-6] vs. 2 [IQR 1-4]; P < 0.001) and more frequent inappropriate empirical therapy (40.7% vs. 3.6%; P < 0.001). Overall, an intravenous-to-oral switch was made within the first week in 172 (55.5%) episodes. In the ESBL group, an oral switch was made in 17 patients (19.7%), while no oral option was available in 48 (55.8%) based on susceptibility results. After adjustment, ESBL was not significantly associated with clinical failure (aOR 1.85, 95% CI 0.33-10.48), recurrence (aOR 1.98, 95% CI 0.70-5.62) or mortality (aHR 2.12, 95% CI 0.43-10.38). However, ESBL-producing Ec-BUTI was associated with longer stays (P = 0.014), higher pharmacy costs (P < 0.001) and independently increased overall hospitalisation costs by a median of €1493 (P = 0.022).

CONCLUSIONS

ESBL-producing Ec-BUTI was associated with greater healthcare resource consumption and costs, though not with worse clinical outcomes. These findings highlight the economic impact of antimicrobial resistance and support antimicrobial stewardship.

Для цитирования: Gómez-Zorrilla Silvia, Rodríguez-Cabalé Grethel, López Montesinos Inmaculada, Alanti Soukaina Sara, Franquet Alejandra, Pascual-Aranda Mariano, Alonso-Carrillo Jesús, Rodríguez-Alarcón Alicia, Sendra Elena, Siverio Ana, Esteban-Cucó Sandra, Sabaté Rosa Ana, Duran-Jordà Xavier, Grau Santiago, Rodríguez-Baño Jesús, Horcajada Juan P, PROA-HMAR. ESBL-producing Escherichia coli bacteraemic urinary tract infections: Clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study.. International journal of antimicrobial agents. 2026. DOI: 10.1016/j.ijantimicag.2026.107787.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.